Epilepsy

The chief medical officer at Stoke Therapeutics sat down at AES 2024 to discuss the promising data behind STK-001, an investigational antisense oligonucleotide in development for Dravet syndrome.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on neurostimulation to treat epilepsy.

Epileptologists Siddharth Jain, MD, MBBS, and Cemal Karakas, MD, provided commentary on a poster presentation at AES 2024 focusing on factors influencing seizure freedom in children who’ve experienced neonatal and perinatal arterial strokes.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 13, 2024.

Hugo Xi, head of Medical Neurology at UCB, discussed the company’s groundbreaking research, innovations in epilepsy care, and the company’s commitment to advancing treatments for rare syndromes at the 2024 AES Annual Meeting.

The pediatric epileptologist at Johns Hopkins Medicine discussed common triggers and potential preventive measures of status epilepticus in LGS, as well as the importance of involving families and caregivers. [WATCH TIME: 4 minutes]

The director of epilepsy surgery at Allegheny Health Network discussed how clinicians can successfully pinpoint the source of epilepsy in the brain through innovative procedures like stereo electroencephalography.

The assistant professor of neurosurgery and neuroscience at Mayo Clinic Arizona provided context on the potential of regenerative therapies like stem cells to restore neural function in patients with epilepsy. [WATCH TIME: 3 minutes]

Most treatment-emergent adverse events were mild or moderate, with low rates of serious TEAEs leading to discontinuation (1.7% in DS and 2.2% in LGS patients).

New data from the phase 3 SKYLINE study suggests soticlestat as a promising adjunctive therapy for seizures among children and young adults living with Dravet syndrome.

The chief medical officer at Stoke Therapeutics provided commentary on the promising mechanism of action of STK-001, an antisense agent, in the treatment of Dravet syndrome. [WATCH TIME: 3 minutes]

Factors like education level, hypertension, diabetes, and depression did not significantly predict epilepsy risk in patients with dementia.

Brad Chapman, head of U.S Epilepsy and Rare Syndromes at UCB, provided context on some of the innovative research and studies being presented at the 2024 American Epilepsy Society Annual Meeting.

The pediatric epileptologist at Johns Hopkins Medicine provided clinical insight on a presentation from AES 2024 that identified and addressed potential triggers of status epilepticus in patients with Lennox-Gastaut syndrome. [WATCH TIME: 4 minutes]

In both the randomized controlled trial and open-label extension, a higher proportion of patients without VNS achieved at least 50% and 75% seizure reductions compared to those with concomitant VNS treatment.

The Le Bonheur Chair in Pediatric Neurology at the University of Tennessee Health Science Center highlighted the benefits and challenges of using stiripentol, an FDA-approved treatment for Dravet syndrome. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Fenfluramine showed a consistent safety profile in treating Lennox-Gastaut syndrome, with common adverse events such as decreased appetite, fatigue, and somnolence.

The epileptologist at UCLA Health provided perspective on a poster presented at AES 2024 that characterized a specific subgroup of patients with developmental epileptic encephalopathy and their response to certain therapies. [WATCH TIME: 3 minutes]

A recent study presented at AES 2024 revealed that plasma p-tau217 linked to memory decline and sleep disruptions in late-onset epilepsy, highlighting its potential as a biomarker.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the American Epilepsy Society (AES) annual meeting.

Participants in the intervention group also reported themes of increased connectivity, creativity, and positivity.

Treatment with relutrigine resulted in a 46% placebo-adjusted reduction in motor seizures, along with a well-tolerated safety profile with adverse events that were mild to moderate.

The director of epilepsy surgery at Allegheny Health Network talked about research recently presented at AES 2024 on stereo-electroencephalography, a minimally invasive treatment for patients with epilepsy. [WATCH TIME: 7 minutes]

Treatment with bexicaserin, a highly selective 5-HT2c receptor superagonist, resulted in reduction in countable motor seizures in patients not previously exposed to the agent.

In a further date from the ongoing open-label extension of the phase 2b X-TOLE study, results demonstrated that the majority of treatment-emergent adverse events associated with azetukalner were mild or moderate.

A recent study presented at AES 2024 showed that fewer than 15% of doses of diazepam nasal spray administered to pediatric patients with epilepsy required a second dose in 24 hours.

CBD maintained a favorable safety profile, with 63% of participants experiencing adverse events such as diarrhea, vomiting, decreased appetite, and lethargy, leading to discontinuation in four patients.